Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00215579
Status:
COMPLETED
Last Update Posted:
2014-09-22
First Post:
2005-09-14
Brief Title:
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
Sponsor:
Duke University
Organization:
Duke University
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
As many as 75 percent of patients with schizophrenia have difficulty taking their oral medication on a regular basis This may lead to worsening of symptoms Clinicians commonly respond to these problems by adding adjunctive medications despite the absence of systematic studies that support such practices It is possible however that in many of these cases the unstable course andor unsatisfactory treatment response reflects incomplete adherence with the originally prescribed oral antipsychotic rather than a need for adjunctive medications This study will examine whether switching patients who demonstrate an unstable course andor an unsatisfactory clinical response to a long-acting injectable preparation as the primary antipsychotic may enhance medication adherence and improve outcomes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RIS-SCH-421 | OTHER | Study specific ID | None |